Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis

IMPORTANCE: The cardiovascular outcome in selected populations when sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are emerging as standard therapy is not clearly understood. It is important to learn the magnitude of cardiovascular benefit using SGLT2-Is across the select subgroups that includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-Akchar, Mohammad, Deshpande, Radhika, Niaz, Zurain, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733833/
https://www.ncbi.nlm.nih.gov/pubmed/34985519
http://dx.doi.org/10.1001/jamanetworkopen.2021.42078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733833/
https://www.ncbi.nlm.nih.gov/pubmed/34985519
http://dx.doi.org/10.1001/jamanetworkopen.2021.42078

Ejemplares similares